Ranibizumabe intravítreo como tratamento adjuvante para glaucoma neovascular

The purpose of this study was to describe a prospective case series of 5 eyes treated with intravitreal ranibizumab injection for neovascular glaucoma (NVG). Five patients with clinically uncontrolled NVG secondary to proliferative diabetic retinopathy (4 patients) and central retinal vein occlusion (1 patient), non-responsive to maximal tolerable medication and panretinal photocoagulation, received intravitreal ranibizumab injection (0.5 mg). Patients were seen at 1st, 3rd and 7th day after the ranibizumab injection and when it was necessary. Success was defined as intraocular pressure (IOP) 21 mmHg, apesar da medicação máxima tolerada, foram submetidos à trabeculectomia com mitomicina C (MMC) 0,5mg/mL por 1 minuto. Falência foi definida como PIO > 21 mmHg, phthisis bulbi, perda da percepção de luz ou necessidade de cirurgia antiglaucomatosa adicional. O resultado primário avaliado foi o controle da PIO após 6 meses do procedimento. A PIO média antes da injeção era de 37 mmHg (DP=7 mmHg). Dois pacientes foram submetidos somente a injeção intravítrea de ranibizumabe, obtendo controle da PIO após o procedimento. Três pacientes foram submetidos à trabeculectomia com MMC no 7º dia após a injeção. Após 6 meses de seguimento, a PIO média era de 12 mmHg (DP=3 mmHg). Todos os olhos mostraram regressão da rubeosis iriana e controle da PIO. A acuidade visual melhorou em 2 olhos, piorou em 1 olho e permaneceu estável em 2 olhos. Estas informações sugerem que a injeção intravítrea de ranibizumabe pode ser uma ferramenta útil no tratamento do GNV.11912

'E-learning' como um complemento do ensino presencial de prevenção da cegueira: ensaio clínico

OBJECTIVE: To investigate if E-learning material improves the basal student knowledge level before attending the presential class of blindness prevention (BP) and if helps to fix this information one-month after the class. METHODS: Fourth-year medical students were randomly assigned to have a presential class of BP (Traditional group = TG) or to have a presential class of BP plus an additional E-learning material (E-learning group = ELG). This material was e-mailed one week before the presential class. The students were submitted to a multiple-choice test (with three options each) with seven questions immediately before the presential class, immediately after the class, and one-month later. The three tests had the same questions; however, the answers options were distributed in different sequences. The primary outcome was immediate pretest score. The secondary outcomes were immediate posttest score and one-month posttest score. RESULTS: Among the 120 fourth-year medical students, a random sample of 34 students was assigned to the TG and 34 students was assigned to the ELG. The two groups showed similar immediate posttest score (TG=6.8 and ELG=6.9; P<.754), but the differences at the immediate pretest score (TG=3.6 and ELG=4.7; P<.001), and at the one-month posttest score, were significant (TG=6.1 and ELG=6.8; P<.001). CONCLUSIONS: The pretest and the one-month posttest results suggested that the E-learning material acts as an effective complementary tool of the presential class of blindness prevention.OBJETIVO: Avaliar se um material disponibilizado através de E-learning antes de aulas presenciais de prevenção da cegueira (PC) melhora o nível de conhecimento basal dos estudantes, e ajuda a manter esse conteúdo um mês após a aula. MÉTODOS: Estudantes do quarto ano do curso médico foram aleatoriamente sorteados para ter aulas presenciais de PC (grupo tradicional = GT) ou ter aulas presenciais precedidas de material adicional por E-learning (grupo E-learning = GEL). Este material foi enviado por correio eletrônico uma semana antes da aula presencial. Os estudantes foram submetidos a testes de múltipla escolha com sete questões (com três alternativas cada) imediatamente antes da aula presencial, imediatamente após a aula, e um mês após a aula. Os três testes tiveram as mesmas questões: entretanto, as respostas foram distribuídas em sequências diferentes. O desfecho primário foi a nota do pré-teste. Os desfechos secundários foram as notas dos pós-teste imediato e do pós-teste tardio. RESULTADOS: Entre os 120 alunos do quarto ano de medicina, uma amostra aleatória de 34 alunos foi selecionada para o grupo GT e 34 alunos para o grupo GEL. Os dois grupos obtiveram nota similar no pós-teste imediato (GT=6.8 e GEL=6.9; P<.754), porém diferenças estatisticamente significativas no pré-teste (GT=3.6 e GEL=4.7; P<.001), e no pós-teste tardio (GT=6.1 e GEL=6.8; P<.001). CONCLUSÃO: Os resultados do pré-teste e do pós-teste tardio sugerem que o E-learning pode ser um complemento eficiente do ensino presencial de prevenção da cegueira.343

Topical corticosteroids for adenoviral keratoconjunctivitis : systematic review

Orientador: Rodrigo Pessoa Cavalcanti LiraDissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciências MédicasResumo: Introdução: Corticosteróides tópicos são utilizados comumente no tratamento da ceratoconjuntivite viral aguda. Tem sido sugerida a utilidade dos corticosteróides no tratamento sintomático da conjuntivite alívio dos sinais e/ou sintomas e prevenção dos infiltrados subepiteliais. Por outro lado, observou-se o relato dos possíveis efeitos colaterais, como o prolongamento da transmissão invitro do vírus e, no âmbito da medicina clínica, ensaios clínicos revelaram a eficácia duvidosa dos colírios de corticosteróides. O objetivo deste estudo foi comparar o uso dos corticosteróides tópicos, com quaisquer drogas usadas nos ensaios clínicos com o placebo. Objetivo: Avaliar se os corticosteróides tópicos são eficazes e seguros para o tratamento da ceratoconjuntivite adenoviral para melhorar os sintomas e evitar ou minimizar complicações relacionadas à doença. Desenho: Revisão sistemática. Métodos: Pesquisa documental na Cochrane Central Register of Controlled Trials (CENTRAL) (que contém o Cochrane Eyes and Vision Group Trials Register), MEDLINE, EMBASE, PubMed, nas listas de referência de relatórios de ensaio identificados e no o Science Citation Index. Foram incluídos ensaios clínicos aleatorizados comparando quaisquer apresentações de corticosteróides tópico com quaisquer outras formas de tratamentos da ceratoconjuntivite adenoviral aguda. Resultados: Foram incluídos ensaios clínicos randomizados onde os corticosteróides tópicos foram comparados com placebo no tratamento da ceratoconjuntivite adenoviral aguda. A busca digital inicial identificou quatro ensaios clínicos comparando corticosteroides e placebo no manejo da ceratoconjuntivite epidêmica somando 243 pacientes. Uma revisão sistemática foi realizada. Conclusão: Nenhum estudo mostrou melhora no alívio dos sinais ou sintomas. A prevenção dos infiltrados subepiteliais permanece controversa, mostrando mais comumente um adiamento na história natural da doença do que uma modificação nela. O uso destes colírios deve ser recomendado com cautela e novos ensaios clínicos são necessários para comprovar sua eficáciaAbstract: Introduction: Topical corticosteroids are commonly used in the treatment of acute viral keratoconjunctivitis. It has been suggested the usefulness of corticosteroids in symptomatic relief of the signs of conjunctivitis and / or symptoms and prevention of subepithelial infiltrates. On the other hand, we observed the reported possible side effects, such as the extension of transmission of the virus in vitro, and beside that, clinical trials showing the effectiveness of corticosteroids eye drops. The aim of this study was to compare the use of topical corticosteroids, with any drugs used in clinical trials with placebo. Objective: To assess whether topical corticosteroids are effective and safe for the treatment of adenoviral keratoconjunctivitis to improve symptoms and prevent or minimize complications related to the disease. Design: Systematic review. Methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group Trials Register), MEDLINE, EMBASE, PubMed and the reference lists of identified trial reports. We used the Science Citation Index to look for articles that cited the relevant studies. We included masked randomized controlled trials in which any form of topical corticosteroid treatment had been compared with placebo in the management of acute adenoviral ceroconjuctivitis. Results: Were included randomized controlled trials in which any form of topical corticosteroid treatment had been compared with placebo in the management of acute adenoviral keratoconjunctivitis. The initial digital search identified 4 clinical trials comparing corticosteroids and placebo in the management of Epidemic keratoconjunctivitis totaling 243 patients. A narrative review was conducted. Conclusion: No study has shown improvement in relief of the signs or symptoms. Prevention of subepithelial infiltrates remains controversial, most commonly showing a delay in the natural history of disease than a change in it. The use of eye drops should be recommended with caution and new clinical trials are needed to prove its effectivenessMestradoOftalmologiaMestre em Ciências Médica

Intravitreal ranibizumab as adjuvant treatment for neovascular glaucoma

The purpose of this study was to describe a prospective case series of 5 eyes treated with intravitreal ranibizumab injection for neovascular glaucoma (NVG). Five patients with clinically uncontrolled NVG secondary to proliferative diabetic retinopathy (4 patients) and central retinal vein occlusion (1 patient), non-responsive to maximal tolerable medication and panretinal photocoagulation, received intravitreal ranibizumab injection (0.5 mg). Patients were seen at 1st, 3rd and 7th day after the ranibizumab injection and when it was necessary. Success was defined as intraocular pressure (IOP) 21, despite maximal tolerable medication, underwent trabeculectomy with 0.5mg/ml mitomycin C (MMC) for 1 minute. Failure was defined as IOP > 21 mmHg, phthisis bulbi, loss of light perception or additional glaucoma surgery. The primary outcome was 6-month IOP control. Mean IOP before the ranibizumab injection was 37 mmHg (7 mmHg SD). Two out of five eyes underwent only ranibizumab injection, having an IOP control after the procedure. Three patients were submitted to trabeculectomy with MMC on the 7th day after the injection. At 6-month follow-up, the mean IOP was 12mmHg (3 mmHg SD). All eyes showed regression of rubeosis iridis and IOP control. Visual acuity improved in 2 eyes worsened in 1 eye, and remained stable in 2 eyes. These data suggest that intravitreal ranibizumab injection may be a useful tool in the treatment of NVG

Association Of Loc387715/arms2 (rs10490924) Gene Polymorphism With Age-related Macular Degeneration In The Brazilian Population.

Abstract Background: An association between LOC387715/ARMS2 (rs10490924) gene polymorphism and AMD has been reported. The aim of this study was to evaluate whether this polymorphism is associated with AMD in a Brazilian cohort. Materials and Methods: In total, 126 unrelated AMD patients (mean age 74.17 ± 7.64) were compared with 86 healthy controls (mean age 71.82 ± 7.12). Study subjects were classified according to the International ARM Epidemiological Study Group definition for early and late-stage AMD. LOC387715/ARMS2 rs10490924 polymorphism was evaluated through polymerase chain reaction and direct sequencing. Results: The T allele frequency was significantly higher in AMD patients than in controls (39.6% compared to 20.3%). The odds ratio (OR) for AMD was 2.05 (95% CI 1.13-3.71) for heterozygotes (TG) and 8.32 (95% CI 2.30-45.99) for homozygotes (TT). Conclusions: These results suggest that there is a contribution of the rs10490924 SNP of the LOC387715/ARMS2 gene to AMD susceptibility in this sample of the Brazilian population.1-

E-learning as a complement to presential teaching of blindness prevention: a randomized clinical trial

OBJECTIVE: To investigate if E-learning material improves the basal student knowledge level before attending the presential class of blindness prevention (BP) and if helps to fix this information one-month after the class. METHODS: Fourth-year medical students were randomly assigned to have a presential class of BP (Traditional group = TG) or to have a presential class of BP plus an additional E-learning material (E-learning group = ELG). This material was e-mailed one week before the presential class. The students were submitted to a multiple-choice test (with three options each) with seven questions immediately before the presential class, immediately after the class, and one-month later. The three tests had the same questions; however, the answers options were distributed in different sequences. The primary outcome was immediate pretest score. The secondary outcomes were immediate posttest score and one-month posttest score. RESULTS: Among the 120 fourth-year medical students, a random sample of 34 students was assigned to the TG and 34 students was assigned to the ELG. The two groups showed similar immediate posttest score (TG=6.8 and ELG=6.9; P<.754), but the differences at the immediate pretest score (TG=3.6 and ELG=4.7; P<.001), and at the one-month posttest score, were significant (TG=6.1 and ELG=6.8; P<.001). CONCLUSIONS: The pretest and the one-month posttest results suggested that the E-learning material acts as an effective complementary tool of the presential class of blindness prevention

Association of LOC387715/ARMS2 (RS10490924) gene polymorphism with age-related macular degeneration in the brazilian population

An association between LOC387715/ARMS2 (rs10490924) gene polymorphism and AMD has been reported. The aim of this study was to evaluate whether this polymorphism is associated with AMD in a Brazilian cohort. In total, 126 unrelated AMD patients (mean age 74.17 +/- 7.64) were compared with 86 healthy controls (mean age 71.82 +/- 7.12). Study subjects were classified according to the International ARM Epidemiological Study Group definition for early and late-stage AMD. LOC387715/ARMS2 rs10490924 polymorphism was evaluated through polymerase chain reaction and direct sequencing. The T allele frequency was significantly higher in AMD patients than in controls (39.6% compared to 20.3%). The odds ratio (OR) for AMD was 2.05 (95% CI 1.13-3.71) for heterozygotes (TG) and 8.32 (95% CI 2.30-45.99) for homozygotes (TT). These results suggest that there is a contribution of the rs10490924 SNP of the LOC387715/ARMS2 gene to AMD susceptibility in this sample of the Brazilian population363224228CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO - CNPQ472645/200

Effect of preoperative use of topical prednisolone acetate, ketorolac tromethamine, nepafenac and placebo, on the maintenance of intraoperative mydriasis during cataract surgery: A randomized trial

Purpose: To compare the effects of preoperative use of topical anti-inflammatory prednisolone acetate, ketorolac tromethamine, nepafenac and placebo, on the maintenance of intraoperative mydriasis during cataract surgery. Design: Randomized clinical trial. Materials and Methods: This single-center, masked, randomized clinical study comprised 140 patients scheduled for cataract surgery. Patients (35 in each group) were randomized to receive placebo, prednisolone acetate, ketorolac tromethamine 0.4% or nepafenac. These eye drops were administered three times daily for the two days prior to surgery. The pupillary diameters were measured by the surgeon using a compass prior to the corneal section and at the end of surgery. The primary outcome was the number of patients with pupil ≥ 6mm at the end of the surgery; the secondary outcome was the number of patients with pupil ≥ 6mm at the beginning of the surgery. Results: All the patients achieved pupil ≥ 6mm at the beginning of the surgery. The number of patients in the prednisolone (29/35), nepafenac (31/35) and ketorolac (30/35) groups with pupil ≥ 6mm was greater than in the placebo group in the maintenance of intraoperative mydriasis (19/35 - P =0.003). There was no statistical difference among the prednisolone, nepafenac and ketorolac groups in the maintenance of intraoperative mydriasis (P =.791). There were no complications during surgery or related to the preoperative use of the eye drops. Conclusion: Preoperative use of ketorolac, prednisolone and nepafenac was effective in maintaining intraoperative mydriasis when compared with placebo